NCT03934359View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 18, 2019

Primary Completion Date

August 30, 2022

Study Completion Date

October 30, 2022

Conditions
Advanced Solid Tumors
Interventions
DRUG

DN1508052-01

DN1508052-01 will be administered subcutaneously on Day 1, Day 8 and Day 15 of each cycle.

Trial Locations (3)

20237

Washington University School of Medicine - Siteman Cancer Center, St Louis

92093

University of California San Diego-Moores Cancer Center, La Jolla

98109

University of Washington - Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
lead

Shanghai De Novo Pharmatech Co., Ltd.

INDUSTRY

NCT03934359 - A Study to Evaluate the Safety, Tolerability of DN1508052-01 in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter